You are here: Industry Insights > BCMA

News List

Domestic Enterprises Have Fully Laid out the Blue Ocean of US$10 Billion, and CAR-T Therapy Must Overcome the Achilles' Heel of Solid Tumor 203 Spuer/PharmaSources
August 07, 2023
The solid tumor is one of the two most deeply developed fields in CAR-T therapy, thus it is extremely urgent to overcome solid tumor in CAR-T therapy, considering domestic market access policy and current biomedical capital environment.
IASO, Innovent CART-cell Therapy Gets Orphan Designation contractpharma
February 14, 2022
anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed and/or refractory multiple myeloma.
Bristol Myers Squibb and bluebird bio get US FDA nod for Abecma (idecabtagene vicleucel) to treat relapsed or refractory multiple myeloma expresspharma
March 29, 2021
Abecma is a first-in-class BCMA-directed personalised immune cell therapy delivered as a one-time infusion for triple-class exposed patients with multiple myeloma.
Ide-cel provides lasting remissions in multiply-relapsed myeloma europeanpharmaceuticalreview
February 26, 2021
BMS and bluebird bio have applied to the FDA for approval of ide-cel as a standard therapy for relapsed or refractory multiple myeloma based on positive Phase II trial results.
SpringWorks Therapeutics in pact with Janssen to assess Nirogacestat with Teclistamab in patients with relapsed or refractory multiple myeloma expresspharma
September 15, 2020
Third collaboration to evaluate nirogacestat in combination with BCMA therapies across modalities.